Le Lézard
Classified in: Health
Subject: ACC

Bioretec Ltd's Annual Report and Financial Statements 2023 published


Bioretec Ltd Company announcement 15 March 2024 at 5:30 p.m. EET

TAMPERE, Finland, March 15, 2024 /PRNewswire/ -- Bioretec Ltd has today published its 2023 Annual Report, Financial Statements and Report by the Board of Directors. The publications are attached to this release and also available in Finnish and English on the company's website at www.bioretec.com/investors/investors-in-english/reports-and-presentations.

Further enquiries

Timo Lehtonen, CEO, +358 50?433 8493
Johanna Salko, CFO, +358 40 754 8172

Certified adviser

Nordic Certified Adviser AB, +46 70 551 67 29

Bioretec in brief

Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable orthopedic implants. The company has built unique competencies in the?biological interface?of active implants?to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.?

Bioretec is?developing?the new RemeOstm?product line?based on a magnesium alloy and hybrid composite, introducing a new generation of strong biodegradable materials for enhanced surgical outcomes. The RemeOstm implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential to make titanium implants redundant and help clinics reach their Value-Based Healthcare targets while focusing on?value for patients through efficient healthcare. The first RemeOstm product market authorization has been received in the U.S. in March 2023, and in Europe, CE mark is expected to be received during the second quarter of 2024. Bioretec is positioning itself to enter the addressable over USD 7 billion global orthopedic trauma market and to become a game changer in surgical bone fracture treatment.

Better healing ? Better life. www.bioretec.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bioretec/r/bioretec-ltd-s-annual-report-and-financial-statements-2023-published,c3946950

The following files are available for download:

https://mb.cision.com/Main/20509/3946950/2673900.pdf

Bioretec financial statements 2023

https://mb.cision.com/Public/20509/3946950/89df36a5327888dd.pdf

Bioretec vuosikertomus 2023 EN

 

SOURCE Bioretec


These press releases may also interest you

at 20:26
/C O R R E C T I O N -- Mitsubishi Tanabe Pharma America/
In the news release, Mitsubishi Tanabe Pharma America to Present RADICAVA ORS® (edaravone) Real-World Data at the Professional Society for Health Economics and Outcomes Research 2024 Annual Meeting, issued 03-May-2024 by Mitsubishi Tanabe Pharma...

at 20:00
Affiliated Dermatologists Notifies of Data Security Incident
Affiliated Dermatologists (AD) is providing notice of a recent data security incident. At this time, AD is not aware of any misuse of any personal information in connection with this incident. What Happened? On March 5, 2024, AD detected it was the...

at 19:19
Statement: The Government of Canada provides an update on the Highly Pathogenic Avian Influenza
With recent news of dairy cattle in the United States testing positive for the Highly Pathogenic Avian Influenza (HPAI) and reports of fragments of HPAI detected in pasteurized milk sold in the U.S., we understand that Canadians may be concerned...

at 19:01
Butterfly Medical Welcomes Experienced Urology Executive to its Helm
Butterfly Medical Ltd, an early-stage medical device company focused on alleviating suffering in patients with BPH (Benign Prostatic Hyperplasia), is excited to announce the hiring of Patrick MacCarthy as CEO. ...

at 18:33
BioVaxys Technology Corp. Closes First Tranche of Private Placement
BioVaxys Technology Corp. (FRA: 5LB) (the "Company") is pleased to announce that it has closed the first tranche (the "First Tranche") of its previously announced non-brokered private placement (the "Private Placement") with the issuance of...

at 18:29
FILAMENT HEALTH ANNOUNCES CHANGE TO BOARD OF DIRECTORS
Filament Health Corp. (Cboe CA: FH) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that Chris Wagner has stepped down from his position as Director on the Company's board of directors...

More news about Health...


News published on and distributed by: